- ICH GCP
- US Clinical Trials Registry
- Search trials
Search clinical trials for: poly I-poly C12U
Total 1303 results
-
Korea University Anam HospitalTakeda; Korean Cancer Study GroupNot yet recruiting
-
The University of Hong KongRecruitingEndometrial CancerHong Kong
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingMetastatic Breast Cancer in Germline-PALB2 Mutations Carriers
-
Tianjin Huanhu HospitalRecruiting
-
Royal Marsden NHS Foundation TrustRecruitingOvarian Cancer | Fallopian Tube Cancer | Peritoneal CancerUnited Kingdom
-
Institute of Cancer Research, United KingdomAstraZeneca; Cancer Research UKRecruitingGynaecological CancersUnited Kingdom
-
University of UtahClovis Oncology, Inc.Terminated
-
Mario Negri Institute for Pharmacological ResearchNorth Eastern German Society of Gynaecological OncologyActive, not recruitingOvarian Cancer | Fallopian Tube Cancer | Primary Peritoneal CarcinomaItaly, Germany
-
Dana-Farber Cancer InstituteTesaro, Inc.Active, not recruiting
-
Matthew GalskyIcahn School of Medicine at Mount Sinai; AstraZenecaCompletedMetastatic Urothelial CancerUnited States
-
AstraZenecaCompletedBRCA or HRR+ Mutated Ovarian Cancer PatientsItaly, Spain, Canada, Czechia, Poland, United Kingdom, Hungary, Bulgaria
-
PfizerTerminated
-
UNICANCERClovis Oncology, Inc.; Fondation ARCCompletedMetastatic Breast CancerFrance
-
AstraZenecaNo longer availablePSR Ovarian Cancer With a BRCA MutationJapan
-
Gustave Roussy, Cancer Campus, Grand ParisUnknownNon Small Cell Lung CancerFrance
-
Dana-Farber Cancer InstituteWithdrawnOvarian Cancer | Fallopian Tube Cancer | Peritoneal CancerUnited States
-
Sunnybrook Health Sciences CentreGlaxoSmithKlineRecruitingOvarian Cancer | Stage IV Ovarian Cancer | High Grade Ovarian Serous Adenocarcinoma | Stage III Ovarian CancerCanada
-
Zhejiang Cancer HospitalSun Yat-sen University; Fujian Cancer Hospital; Hunan Cancer Hospital; Zhejiang... and other collaboratorsNot yet recruitingTriple Negative Breast Cancer | Homologous Recombination Deficiency
-
SOLTI Breast Cancer Research GroupRecruitingMetastatic Breast Cancer | Triple Negative Breast Cancer | HER2-negative Breast CancerSpain
-
Ling-Ying WuNot yet recruiting
-
Yonsei UniversityNot yet recruitingTNBC - Triple-Negative Breast CancerKorea, Republic of
-
Tongji HospitalSun Yat-sen University; Qilu Hospital of Shandong University; Hubei Cancer Hospital and other collaboratorsRecruiting
-
Laval UniversityCanadian Institutes of Health Research (CIHR); AstraZenecaRecruiting
-
Dana-Farber Cancer InstituteAstraZenecaWithdrawnUveal Melanoma | Cutaneous Melanoma | Mucosal Melanoma | Recurrent Metastatic MelanomaUnited States
-
AstraZenecaActive, not recruitingOvary CancerFrance, United Kingdom
-
PfizerCompleted
-
Abramson Cancer Center at Penn MedicineTerminatedPancreatic CancerUnited States
-
Memorial Sloan Kettering Cancer CenterClovis Oncology, Inc.Active, not recruiting
-
Wake Forest University Health SciencesEmory UniversityCompletedBrain TumorsUnited States
-
University of Texas Southwestern Medical CenterCompletedBreast Cancer | Ovarian CancerUnited States
-
Hellenic Cooperative Oncology GroupActive, not recruitingOvarian CancerGreece
-
AstraZenecaCompletedRelapsed Ovarian Cancer, BRCA Mutation, Platinum SensitivityUnited States, Canada
-
AstraZenecaCompleted
-
Valduce HospitalCompleted
-
German Breast GroupGlaxoSmithKline; Stemline Therapeutics, Inc.Not yet recruitingBRCA1 Mutation | BRCA2 Mutation | PALB2 Gene Mutation | Hormone Receptor Positive HER-2 Negative Breast Cancer | Advanced or Metastatic Breast CancerGermany
-
Tango Therapeutics, Inc.RecruitingBreast Cancer | Ovarian Cancer | Prostate Cancer | Pancreas Cancer | BRCA1 Mutation | BRCA-Mutated Ovarian Carcinoma | BRCA-Associated Breast Carcinoma | HRD Positive Advanced Ovarian CancerUnited States
-
National Taiwan University HospitalAstraZenecaRecruiting
-
K-Group, Beta, Inc., a wholly owned subsidiary...RecruitingOvarian Cancer | Fallopian Tube Cancer | Platinum-resistant Ovarian Cancer | Primary Peritoneal CarcinomaUnited States, France
-
Sun Yat-sen UniversityRecruitingNasopharyngeal CarcinomaChina
-
Gruppo Oncologico del Nord-OvestRecruitingHead and Neck Squamous Cell CarcinomaItaly
-
National Cancer Institute, NaplesRecruitingBRCA Wild Type Platinum Sensitive Recurrent Ovarian CancerItaly
-
Peter MacCallum Cancer Centre, AustraliaRecruitingMetastatic Castration Resistant Prostate Cancer (mCRPC)Australia
-
National Cancer Institute (NCI)RecruitingLung Neoplasms | Small Cell Lung Cancer | Prostate Cancer | Urothelial Carcinoma | Urothelial CancerUnited States
-
BayerGlaxoSmithKlineTerminatedOvarian Cancer | Advanced Solid Tumors (Excluding Prostate Cancer)United States
-
Sheba Medical CenterCompleted
-
Institut BergoniéNational Cancer Institute, FranceCompleted
-
PfizerMedivation, Inc.Completed
-
AstraZenecaParexelApproved for marketing
-
Medical University of South CarolinaTerminated
-
National Cancer Institute (NCI)Active, not recruitingColorectal Adenoma | Colorectal Adenoma With Severe Dysplasia | Colorectal Tubulovillous AdenomaUnited States, Puerto Rico